Extrait

This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by intravenous (IV) infusion in combination with pertuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced or metastatic breast cancer who had previously received trastuzumab.

Critère d'inclusion

• Metastatic breast cancer

Pays

• Belgium
• Canada
• France
• Germany
• Italy
• Spain
• United States

Liens

• nct
• ictrp